Samsung Biologics has built its business on antibody manufacturing for biologics, the class of drugs that includes most modern cancer and immune therapies.
Peptides are a different discipline entirely, and Samsung has no meaningful capability in the category.
PolyPeptide gives it that instantly: more than 70 years of manufacturing heritage and over 1,000 therapeutic peptides already produced, rather than years spent building the expertise from scratch.
GLP-1 gold rush
The real driver is obesity and diabetes treatment. GLP-1 drugs, the class that includes Ozempic and Wegovy, are peptides, and demand for their manufacture has outstripped the number of specialist producers capable of making them at scale.
The global peptide contract manufacturing market is projected to nearly triple by the mid-2030s, reaching close to $27 billion.
Every large pharmaceutical company racing to launch its own GLP-1 drug needs outsourced capacity, and there are few producers with PolyPeptide's track record able to supply it.
Geography closes the deal
PolyPeptide also brings plants in Sweden, Belgium, France, the United States and India.
That gives Samsung a manufacturing footprint inside its two biggest markets, the US and Europe, rather than relying on exporting from South Korea.
Paying up to move fast
Samsung is paying a substantial premium for that speed: the offer price sits around 40% above where PolyPeptide shares traded in April, before takeover speculation began.
PolyPeptide's own board chair described the deal as reaching scale "we could not reach alone," a signal that the smaller company saw limits to its own growth as clearly as Samsung saw the opportunity.
For Samsung, the calculation is straightforward: buying a functioning peptide platform now is faster, and probably cheaper in the long run, than trying to compete for GLP-1 manufacturing business without one.
